At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antimalarials; Antiprotozoals; Chlorinated hydrocarbons; Diamines; Pyrimidines
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Toxoplasmosis
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Toxoplasmosis in Australia (PO, Tablet)
- 19 Nov 2017 GlaxoSmithKline completes a phase I trial in Toxoplasmosis in Australia (PO) (NCT03258762)
- 25 Sep 2017 Phase-I clinical trials in Toxoplasmosis in Australia (PO) (NCT03258762)